February 23, 2022 -- EyeBiotech (EyeBio) has successfully completed a $65 million series A funding round. The company will use proceeds from the funding round to assemble and develop a diversified pipeline of product candidates that combines scientifically compelling targets with innovative translational approaches.
The funding brings together an international team of executives and investors with an extensive track record for developing ophthalmology therapies. EyeBio launched with a specific mission, to protect, restore, and improve vision for people who are underserved by available eye disease therapies. The company has established a footprint in the U.K. to take advantage of the innovation-friendly environment for its clinical trial development.
The EyeBio management team combines deep experience in ophthalmology with proven innovation and success in clinical development. EyeBio is a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases.
SV Health Investors led the round, alongside Samsara BioCapital and Jeito Capital, with additional financial backing from MRL Ventures.
Copyright © 2022 scienceboard.net